Skip to main content
Sonoma Pharmaceuticals, Inc. logo

Sonoma Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SNOA ISIN · US83558L2043 US Manufacturing
Open in API
Filings indexed 951 across all filing types
Latest filing 2013-12-20 Director's Dealing
Country US United States of America
Listing US SNOA

About Sonoma Pharmaceuticals, Inc.

https://sonomapharma.com/

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and commercializes products based on its patented Microcyn® Technology, a stabilized hypochlorous acid (HOCl) platform. With over 20 years of experience, the company produces a range of prescription and over-the-counter solutions for advanced wound care, dermatology, animal health, and eye care. Its products are designed to manage various conditions by promoting healing and reducing the risk of infection. The portfolio serves healthcare professionals in settings like hospitals and nursing homes, as well as consumers for at-home use.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2013-12-20 English
FORM 4
Director's Dealing
2013-12-20 English
FORM 4
Director's Dealing
2013-12-20 English
FORM 8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The content specifically discusses the company's receipt of a Nasdaq notice regarding non-compliance with listing requirements, details of equity transactions to regain compliance, and the potential risk of delisting if compliance is not maintained. The key section is 'Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing,' which clearly indicates this is a delisting announcement. The document is about the company's stock being at risk of removal from Nasdaq and the steps taken to avoid that. Therefore, the appropriate classification is 'Delisting Announcement' (DLST). The document length and detail confirm it is not a mere announcement of a report but a substantive filing about delisting status.
2013-12-18 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to the issuance and sale of common stock. It includes detailed information about the offering, use of proceeds, risk factors, and corporate information. The presence of terms like 'Prospectus Supplement', 'Rule 424(b)(5)', 'Registration No.', and detailed offering terms indicates this is a capital raising document. It is not a financial report, earnings release, or management discussion, but rather a disclosure related to a financing transaction. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the actual prospectus supplement, not just an announcement of a report.
2013-12-06 English
CURRENT REPORT ON FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 4, 2013. It details the entry into a material definitive agreement involving the issuance of common stock and related warrants, including placement agent commissions and terms of the offering. The content focuses on a financing transaction and does not contain financial statements or comprehensive financial performance data. It is not an earnings release or annual/interim report. The primary subject is a capital raising event and related agreements. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive information about the financing event, not just an announcement or certification, so it is not RPA or RNS.
2013-12-06 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.